• Tirzepatide market performance: Tirzepatide has shown steady ramp-up with April sales growing over March despite new generic semaglutide entrants. Cipla views both molecules as parallel markets that will follow distinct growth trajectories.
• GLP-1 expansion strategy: In India, Cipla is focusing primarily on tirzepatide as its larger commercial opportunity. Globally, the company plans to introduce semaglutide and other GLP-1 offerings as respective patents expire.
• Eli Lilly collaboration: Management declined to comment on potential future tie-ups regarding Eli Lilly's newly launched Alzheimer's drug, but confirmed its commitment to building on existing partnerships.
• Geopolitical cost pressures: Cipla is currently mitigating disruptions from the West Asia conflict using existing inventory buffers and purchase agreements rather than invoking force majeure. The company is prepared to negotiate pricing pass-throughs with customers to maintain supply security if cost pressures persist.